Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Life Science Institute announces beginning of exploratory study of CL-2020

Jan. 19, 2018

Vasade Biosciences discloses novel adenylate cyclase inhibitors

Jan. 18, 2018

Phase II LIBERTY study of ubenimex in PAH does not meet primary endpoint

Jan. 17, 2018

Tenax Therapeutics to develop levosimendan for PH-HFpEF

Jan. 17, 2018

MedImmune studies MEDI-5884 in stable coronary heart disease

Jan. 16, 2018

Zhejiang Hisun Pharmaceutical identifies GCGR antagonists

Jan. 15, 2018

Bristol-Myers Squibb discovers apelin receptor agonists

Jan. 11, 2018

Caladrius studies CLBS-12 in patients with critical limb ischemia

Jan. 11, 2018

Boston Pharmaceuticals obtains rights to Pierre Fabre drug candidate for atrial fibrillation

Jan. 5, 2018

Jiangsu Hengrui Medicine patents ROM-K inhibitors

Jan. 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...